Results 111 to 120 of about 17,175,483 (375)

Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis.

open access: yesBlood Advances, 2020
Despite achieving a hematologic complete response after treatment, many patients with AL amyloidosis do not attain recovery of organ function and/or experience hematologic relapse.
Andrew Staron   +5 more
semanticscholar   +1 more source

Immune checkpoint expression patterns on T cell subsets in light-chain amyloidosis: VISTA, PD-1, and TIGIT as potential therapeutic targets

open access: yesBlood Science
Amyloid light chain (AL) amyloidosis is a rare plasma cell dyscrasia with dismal prognosis. This study aims to investigate the T-cell immune checkpoint expression patterns in systemic AL amyloidosis and its relationship with clinicobiological traits.
Jinghua Wang   +7 more
doaj   +1 more source

An unusual case of chronic lymphocytic leukemia, multiple myeloma and cardiac amyloidosis

open access: yesJournal of Community Hospital Internal Medicine Perspectives, 2017
Light chain amyloidosis has very rarely been reported in association with chronic lymphocytic leukemia (CLL). We reported on a 76-years-old female who presented with simultaneous kappa-restricted chronic lymphocytic leukemia (CLL) and a lambda-restricted
Dongyan Liu   +2 more
doaj   +1 more source

Gastroparesis in a Patient with Gastric AL Amyloidosis

open access: yesCase Reports in Gastroenterology, 2018
Systemic amyloidosis is a group of complex disorders characterized by the extracellular deposition of nonbranching fibrils in various tissues, ultimately leading to a variety of clinical presentations including isolated or multiorgan dysfunction. Amyloid
Matthew Hoscheit   +2 more
doaj   +1 more source

Sex-specific effects of microbiome perturbations on cerebral Aβ amyloidosis and microglia phenotypes. [PDF]

open access: yes, 2019
We demonstrated that an antibiotic cocktail (ABX)-perturbed gut microbiome is associated with reduced amyloid-β (Aβ) plaque pathology and astrogliosis in the male amyloid precursor protein (APP)SWE /presenilin 1 (PS1)ΔE9 transgenic model of Aβ ...
Baufeld, Caroline   +10 more
core   +1 more source

A Case of AL Amyloidosis

open access: yesInternational Journal of Clinical & Medical Imaging, 2015
Case: 45 year old lady presented with anorexia, weakness for last one year and development of deformity in her spine for last one and half years following fracture. On clinical examination she had mild bilateral pedal edema, kyphoscoliosis, tenderness over rib cage on left side.
Vijayan Ganesan   +3 more
openaire   +2 more sources

A Rare Case: Primary Pulmonary Amyloidosis

open access: yesDüzce Tıp Fakültesi Dergisi
Amyloidosis is a rare disorder characterized by the extracellular deposition of insoluble protein aggregates. There are two common types of amyloidosis: Amyloid A (AA) and amyloid light chain (AL).
Ceyda Ceylan   +3 more
doaj   +1 more source

The relationship between amyloid structure and cytotoxicity [PDF]

open access: yes, 2014
Self-assembly of proteins and peptides into amyloid structures has been the subject of intense and focused research due to their association with neurodegenerative, age-related human diseases and transmissible prion diseases in humans and mammals. Of the
Marchante, Ricardo   +3 more
core   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

open access: yesArthritis &Rheumatology, EarlyView.
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y. C. Chen   +2 more
wiley   +1 more source

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.

open access: yesBlood, 2019
Bortezomib is a standard therapy in AL amyloidosis (AL), but little is known about response duration. A difference in involved amyloidogenic and uninvolved serum free light chains (dFLC) less than 10mg/L (low-dFLC response) post-treatment predicts ...
R. Manwani   +12 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy